

1 **Effect of Immunoabsorption on clinical presentation and** 2 **immune alterations in COVID-19-associated ME/CFS**

3 Moritz Anft^{1*}, Lea Wiemers^{1*}, Kamil Rosiewicz^{2*}, Adrian Doevelaar¹, Sarah
4 Skrzypczyk¹, Julia Kurek¹, Sviatlana Kaliszczyk^{1,2}, Maximilian Seidel¹, Ulrik
5 Stervbo^{1,2}, Felix S. Seibert¹, Timm H. Westhoff¹, Nina Babel^{1,2}

6 * These authors contributed equally to the manuscript

7 ¹Center for Translational Medicine and Immune Diagnostics Laboratory, Medical
8 Department I, Marien Hospital Herne, University Hospital of the Ruhr-University
9 Bochum, Hölkeskampring 40, 44625 Herne, Germany

10 ²Berlin Institute of Health, Berlin-Brandenburg Center for Regenerative Therapies,
11 and Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate
12 Member of Freie Universität Berlin, Humboldt-Universität zu Berlin Augustenburger
13 Platz 1, 13353 Berlin, Germany

14
15 Corresponding author:

16 Prof. Nina Babel

17

18 Center for Translational Medicine, Medical Department I, Marien Hospital Herne,
19 University Hospital of the Ruhr-University Bochum, Hölkeskampring 40, 44625
20 Herne, Germany and Berlin Institute of Health, Charité – Universitätsmedizin Berlin,
21 Augustenburger Platz 1, 13353 Berlin, Germany

22

23 Email: nina.babel@rub.de; nina.babel@charite.de

24 Keywords: SARS-CoV-2, Post-Covid, Immunoabsorption

25 **Abstract**

26 Autoreactive antibodies (AAB) are currently being investigated as causative or
27 aggravating factors during post-COVID. In this study we analyze the effect of
28 immunoadsorption therapy on symptom improvement and the relationship with
29 immunological parameters in post-COVID patients exhibiting symptoms of Myalgic
30 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This observational study
31 includes 12 post-COVID patients exhibiting a predominance of ME/CFS symptoms
32 alongside increased concentrations of autonomic nervous system receptors (ANSR)
33 autoantibodies and neurological impairments. We found that following
34 immunoadsorption therapy, the ANSR autoantibodies were nearly eliminated from
35 the patients' blood. The removal of IgG antibodies was accompanied by a decrease
36 of pro-inflammatory cytokines including IL4, IL2, IL1 β , TNF and IL17A serum levels,
37 and a significant reduction of soluble spike protein. Notably, a strong positive
38 correlation between pro-inflammatory cytokines and ANSR-AABs β 1, β 2, M3, and M4
39 was observed in spike protein-positive patients, whereas no such correlation was
40 evident in spike protein-negative patients. 30 days post-immunoadsorption therapy,
41 patients exhibited notable improvement in neuropsychological function and a
42 substantial amelioration of hand grip strength was observed. However, neither self-
43 reported symptoms nor scores on ME/CSF questionnaires showed a significant
44 improvement and a rebound of the removed proteins occurring within a month.

45

46 **Introduction**

47 While the SARS-CoV-2 pandemic has decreased in intensity over time due to
48 vaccinations and the emergence of less pathogenic virus variants, some patients
49 manifest an array of different symptoms several months after the initial COVID-19
50 infection. These sequelae are collectively termed Long- or Post-COVID. The detailed
51 research into Post-COVID reveals it to be a heterogeneous clinical picture with over
52 200 documented different symptoms arising from various causes.¹ These symptoms
53 are often nonspecific and can impact multiple organs. Alongside cardiovascular
54 symptoms like palpitations or chest pain,²⁻⁴ patients often report respiratory issues
55 such as breathlessness.⁵ Importantly, neurological and cognitive symptoms including
56 cognitive decline, memory impairment, and fatigue are prevalent among patients
57 experiencing severe Post-COVID effects, leading to significant limitations and even
58 complete immobilization.⁶⁻⁸ These symptoms associate with autoantibodies against
59 G protein-coupled receptors (GPCRs) of autonomic nervous system.⁹

60 Based on current research findings, four main causes can be broadly distinguished
61 as responsible for the array of symptoms.¹⁰

62 1.) Persistent SARS-CoV-2 virus reservoirs in tissues: Numerous studies have
63 identified SARS-CoV-2 RNA in various tissues,^{11,12} as lung, lymph nodes, and
64 plasma.¹³⁻¹⁵ Additionally, in post-COVID patients, soluble spike protein has been
65 detected in plasma even a year after initial SARS-CoV-2 infection.¹⁶ It is
66 hypothesized that active, persistent reservoirs of SARS-CoV-2 virus exist in the
67 tissues of a significant portion of post-COVID patients, contributing to the
68 development of subsequent post-COVID symptoms.¹⁷

69 2.) Autoantibody (AAB) formation:¹⁸ Infection with SARS-CoV-2 can trigger the
70 formation of autoantibodies targeting components of the immune system, the
71 cardiovascular system, the thyroid gland, as well as rheumatoid-specific
72 autoantibodies and antibodies against G-protein-coupled receptors (GPCR).¹⁹
73 Studies show a correlation in the concentration of GPCR AAB with the severity of
74 neurological symptoms.²⁰

75 3.) Reactivation of latent viruses: Particularly, the reactivation of various herpes
76 viruses like EBV and HHV-6 has been observed in post-COVID patients, correlating
77 with mitochondrial fragmentation and decreased energy metabolism.²¹

78 4.) Tissue damage from inflammatory processes: Post-COVID patients exhibit
79 elevated levels of pro-inflammatory cytokines such as IL-1 β , IL-6, TNF, or IP10,
80 which can lead to neurological and kidney damage or diabetes mellitus.²²⁻²⁴
81 Additionally, microvascular blood clots with endothelial dysfunction have been
82 detected in a substantial number of patients, associated with symptoms like fatigue,
83 thrombosis, and microclots.^{25,26}

84 The presence of autoantibodies in the majority of post-COVID patients makes
85 immunoadsorption (IA) an attractive therapeutic strategy. There are a variety of
86 different adsorbents, allowing the non-selective removal of all subclasses of
87 immunoglobulins such as IgG or more selective removal of disease-specific
88 molecules such as lipoproteins and CRP. In the context of post-COVID syndrome,
89 IgG immunoadsorption is particularly relevant since it can specifically eliminate
90 autoantibodies. However, preliminary reports on the efficacy of IA in post-COVID are
91 contradictory, rising the need to establish a broader scientific basis.²⁷⁻²⁹

92 This study aims to explore the impact of IA on neuropsychological impairments in
93 relation to humoral and cellular immune response in post-COVID patients with
94 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The objective is to
95 explore the impact of IA-therapy on diverse markers associated with post-COVID
96 conditions, including autoantibodies directed against autonomic nervous system
97 receptors, soluble spike protein levels, pro-inflammatory cytokines, and the
98 composition of the cellular immune system, both pre- and thirty days after therapy.

99 **Results**

100 In this study, 12 post-COVID patients with ME/CSF symptoms and high levels of
101 GCPR AAB against autonomic nervous system receptors (ANSR) were evaluated for
102 clinical symptoms, physical and mental health status and immunological
103 characteristics before and after immunoadsorption (IA) therapy. The patients were
104 two-thirds female and with a median age of 50 and a median BMI of 25.25. Among
105 them, 4 out of 12 had ME/CSF developed after SARS-CoV-2 infection, while the
106 remaining 8 described their ME/CSF originally induced by other factors, later
107 aggravated by a subsequent SARS-CoV-2 infection. Table 1 demonstrates patient
108 characteristics and comorbidities. Inclusion criterium was elevated levels of at least 3
109 of the 4 ANSR proteins β 1-adrenergic receptor (>15 U/mL), β 2-adrenergic receptor
110 (>8 U/mL), M3-mACh receptor (>6 U/mL), and M4-mACh receptor (>10.7 U/mL).
111 Over a span of 10 days, patients underwent 5 sessions of IA-therapy, with
112 comprehensive screening conducted prior to the first session, after the last session
113 and 30 days after the last session. Health status and symptoms were assessed
114 through detailed anamnesis, while physical examinations encompassed
115 quantification of handgrip strength. Neurological and mental well-being were
116 quantified via the SF-36 questionnaire and various fatigue scores, while dysfunction
117 of the autonomic nervous system was gauged using the COMPASS-31 score. Blood
118 was immunologically analyzed during both assessments and following the last IA
119 session (Figure 1A).

120 **IA-therapy leads to a strong decrease in ANSR-AABs and to an improvement in** 121 **multiple physical and neuropsychological factors**

122 Quantifying the ANSR autoantibodies in the patients' serum immediately after the
123 final therapy session revealed that the levels of autoantibodies was significantly
124 reduced below their respective threshold values through IA. 30 days later, however,
125 the concentration of autoantibodies had returned to a slightly, but not significantly,
126 lower level compared to the time before therapy (Figure 1B). 30 days after IA-
127 therapy, the patients had median autoantibody levels of 93.9% (β 1), 74.8% (β 2),
128 82.4% (M3), and 88.8% (M4) compared of the baseline levels before IA
129 (Supplemental Table S1). In addition, several physical and neuropsychological were
130 observed following the IA. Patients exhibited significantly increased hand strength

131 post-therapy (Figure 1C). Moreover, the overall score of the CERAD test battery was
132 significantly higher at the one-month follow-up measurement, primarily attributed to
133 enhancements in word learning, fluent speaking, and the Trail Making Test B (Figure
134 1D).

135 **IA-therapy does not lead to self-perceived changes**

136 In addition to these objective measurements, several questionnaires and anamnesis
137 were used to assess patients' self-perception of whether and how their symptoms
138 and physical and mental health changed after the therapy (Table 2). The surveys
139 revealed no significant differences in the perception of physical and mental health
140 following the IA-therapy. Neither in the SF-36 questionnaire regarding health-related
141 quality of life nor in the Chandler Fatigue Score, Bell Score, or the Canadian criteria
142 for ME/CFS showed a significant improvement or deterioration due to the therapy
143 (Table 2 – upper section). Additionally, the self-reported symptoms of the patients did
144 not differ 30 days after the last IA compared to before the therapy (Table 2 – lower
145 section).

146 **Temporary reduction in pro-inflammatory cytokines**

147 The concentration of pro-inflammatory cytokines in the serum of patients was
148 examined before and after the IA. Especially IL-4, IL-2, IL-1 β , TNF and IL-17A were
149 significantly reduced immediately after the IA compared to the pre-therapy level.
150 Similar to the concentration ANSR AABs, the concentration of all these cytokines
151 rose back to a similar level as before the IA-therapy in the follow-up analysis 30 days
152 later. Interestingly, the concentration of TGF β 1 increased significantly directly after IA
153 and dropped back to the pre-IA level in the follow-up analysis, and the concentration
154 of IL-8 was significantly reduced after IA-therapy (Figure 2). The concentration of
155 other cytokines such as IP-10, MCP-1, IL-6 and IL-10 were not changed by the
156 therapy (Supplemental Figure S1). In addition, 5 of the 12 patients had an acute EBV
157 infection with an elevated EBV load during the whole study, and the viral load did not
158 change during and after IA-therapy (Supplementary Figure S2).

159 **Cellular immunity is unaffected by IA**

160 To explore if the perturbations in pro-inflammatory cytokines during IA-therapy had
161 any effect on the composition of T cell populations, the major T cell populations

162 before and 30 days after IA-therapy were examined. While there were no differences
163 in the percentage of total CD4⁺ and CD8⁺ T cells, patients demonstrated significantly
164 more naive and significantly fewer memory CD4⁺ T cells and additionally significantly
165 fewer CXCR5 expressing follicular helper cells in the follow-up examination
166 compared to the data before the start of IA-therapy (Figure 3A+3C).

167 T cells may become exhausted in a prolonged pro-inflammatory.³⁰ We therefore
168 explored whether this is the case in post-COVID before and after IA-therapy. The
169 frequency of PD-1 expression on CD4⁺ and CD8⁺ T-cells prior to the therapy was
170 within previously observed ranges (Figure 3A+C)³¹. Except for a significant decrease
171 in Tim-3 expressing CD4 T cells, there were no differences in the expression of
172 exhaustion markers PD-1, Tim-3, CTLA-4, or Lag-3 directly or 30 days after IA
173 (Figure 3 A+C and Supplemental Figure S3).

174 To investigate if the autoimmunity towards autonomic nervous system receptors
175 extended to the T cells, PBMC were stimulated with pooled lysates of β 1/ β 2-
176 adrenoceptors and muscarinic M3/M4 receptors, respectively (Figure 3B+D).
177 Simultaneously, the potential impact on cellular immunity to SARS-CoV-2 was
178 examined by additionally stimulating of PBMC with a pool of SARS-CoV-2 spike
179 protein overlapping peptides (Figure 3B+D). ANSR specific T cells were quantified by
180 assessing the expression of CD137 on CD8⁺ T cells and CD137 and CD154 on CD4⁺
181 T cells. Following IA-therapy, there were no discernible differences in the
182 percentages of CD4 and CD8 T cells specific to β 1/ β 2-adrenoceptors or muscarinic
183 M3/M4 receptors compared to the respective frequencies before IA-therapy.
184 Moreover, although a slight yet significant decrease was noted specifically in the
185 proportion of naive CD4 T cells targeting M3+M4 after IA, no significant differences
186 were observed in the proportions of naive, memory, and exhausted ANSR-specific T
187 cells post-IA (Figure 3B+D and supplemental Figure S4).

188 **IA-Therapy leads to a temporary reduction of SARS-CoV-2 spike protein**

189 Several studies have shown that a subset of post-COVID patients have detectable
190 levels of soluble spike protein in their blood.^{16,17} The next step was to investigate the
191 development of spike protein levels in the patients in this study before the IA-therapy,
192 immediately after the last IA and at follow-up. Before the first IA, soluble spike protein
193 was detected in 6 out of 12 patients, with a median concentration of 207.7 pg/mL.

194 Following the IA-therapy, the concentration of soluble spike protein significantly
195 dropped to 22.8 pg/mL, but rebounded to a median of 207.5 pg/mL by the 30-day
196 follow-up examination (Figure 4A). Except for one patient, the IA-therapy also
197 significantly reduced the concentration of SARS-CoV-2 spike protein specific
198 antibodies, but these levels also returned to their initial values within the 30 days
199 following IA (Figure 4B). However, we found no differences in the frequency of spike
200 protein specific CD4⁺ or CD8⁺ T cells after the IA-therapy (Figure 4C).

201 **Correlation between neurological symptoms, virological and immunological** 202 **status**

203 As stated above, the ratio of patients identified with soluble spike protein at study
204 start was 50:50, whereas 100% of patients showed detectable SARS-CoV-2 specific
205 antibodies. This interesting result led to the question, if there are possible differences
206 between these two groups based on the detected soluble spike protein (groups
207 named as "spike-" and "spike+"). First, spike+ patients were characterized by
208 significantly strong positive correlations between spike+ protein and SARS-CoV-2
209 specific antibodies, ANSR autoantibodies (β 1, β 2 and M3) and pro-inflammatory
210 cytokines IP-10 and IL-6 (Figure 4D). SARS-CoV-2 specific antibodies showed not
211 only nearly the same significant correlation with ANSR autoantibodies (β 2, M3 and
212 M4) but also with pro-inflammatory cytokines IL-2, IL-1 β , IL-6 and IL-12p70 and a
213 significant negative correlation to the anti-inflammatory cytokine TGF β 1. In general,
214 all ANSR autoantibodies showed very strong correlations to all cytokines except for
215 MCP-1, INF γ and TGF β 1. This result was in strong contrast to spike- patients. Here,
216 SARS-CoV-2 spike protein specific antibody levels correlated only positively with
217 blood levels of IL-1 β and INF γ . Interestingly, ANSR autoantibody levels (β 2, M3, M4)
218 showed a significant negative correlation to TGF β 1 blood levels. Only the positive
219 correlation between ANSR autoantibody levels and SARS-CoV-2 specific antibody
220 levels had spike- and spike+ patients in common (Figure 4D).

221 Next, the detected levels of soluble spike protein, SARS-CoV-2 specific antibodies
222 and ANSR autoantibodies were correlated with the monitored clinical ME/CSF data.
223 Again, spike+ patients showed a slightly different correlation profile than spike-
224 patients. Soluble spike protein levels correlated significantly positive with MBSQ total
225 score, while significantly negative with CERAD-Plus score and CERAD-Plus (word
226 list learning) (Figure 4E).

227 This study shows that TheraSorb IA-therapy has the potential to improve the
228 neuropsychological state of ME/CFS, but has no positive impact on self-perceived
229 symptoms and mental health. In addition to ANSR-AABs, it effectively removes the
230 soluble spike protein, decreases pro-inflammatory cytokines and increase
231 inflammatory cytokine TGF β . However, these improvements are highly transient, with
232 a resurgence of the eliminated proteins happening within a month. Further
233 therapeutic steps are needed to be implemented to provide a long-term
234 immunological and symptomatic improvements

235 **Discussion**

236 Although the SARS-CoV-2 pandemic is over, humankind is still struggling with its
237 consequences years later. The occurrence of post-COVID after SARS-CoV-2
238 infections poses major challenges for both patients and healthcare providers. The
239 multiple symptoms and underlying causes make diagnosis and treatment complex
240 and difficult. ANSR autoantibodies are associated with disease severity in ME/CSF
241 and their removal is associated with moderate improvement in symptoms in a
242 previous study.²⁸ The present study shows that the health status of post-COVID
243 patients with ME/CFS symptoms and high ANSR autoantibody levels objectively
244 improved after IA-therapy. However, the affected patients did not perceive any
245 improvement as reflected in the self-reported symptoms.

246 In the present study, all patients had high titers of ANSR autoantibodies against
247 β 1/ β 2-adrenoceptor and muscarinic M3/M4 receptor. These ANSR and other GPCR
248 autoantibodies were earlier associated with the occurrence and worsening of multiple
249 diseases like cardiovascular or rheumatic diseases,^{32–34} and several studies have
250 shown a correlation between the presence of these ANSR autoantibodies and the
251 severity of post-COVID.^{9,35–37} In the context of ME/CSF and post-COVID, it has been
252 shown that ANSR autoantibodies may be associated with Postural Orthostatic
253 Tachycardia Syndrome (POTS).^{38,39} It is suggested that these ANSR autoantibodies
254 can disrupt autonomic nervous system function by interfering with signaling pathways
255 through binding to ANSRs, leading to symptoms such as excessive increase in heart
256 rate upon standing, dizziness, and fatigue.⁴⁰ The patients in this study also reported
257 these neurological and hemodynamic symptoms and were diagnosed with fatigue.
258 Self-assessments using the SF-36 questionnaire revealed substantial deficits in both
259 physical and mental health. Additionally, the Bell and Chalder Fatigue Scores were
260 low, consistent with findings from studies on post-COVID patients with ME/CFS
261 symptoms.⁴¹ IA-therapy could effectively remove ANSR autoantibodies in patients
262 with ME/CSF and provided a moderate improvement in symptoms in the period
263 shortly after therapy.^{28,42} In line with this, an overall score increase in the CERAD+
264 neuropsychological test as well as an increase in hand strength after removal of the
265 ANSR autoantibodies in this study was observed.

266 As also reported in other studies,^{28,42} the levels of autoantibodies returned to their
267 original levels one month after therapy, which could be the reason that in contrast to
268 the improvement of objective symptoms, there was no demonstrated improvement in
269 the quantified fatigue scores and self-reported symptoms by the patients in the
270 follow-up. While neurological symptoms such as tiredness, cephalgia and brain fog
271 were present in almost all patients before therapy, they did not improve by IA-therapy
272 and the removal of ANSR autoantibodies. Accordingly, physical and mental health
273 were at the same low level after IA-therapy as before treatment, suggesting that
274 short-term removal of these AABs from the blood by IA-therapy cannot effectively
275 treat post-COVID symptoms. In contrast, removal of ANSR autoantibodies in a post-
276 COVID patient using the DNA aptamer BC 007 resulted in a significant and four-week
277 lasting improvement in symptoms such as fatigue symptoms, taste and capillary
278 microcirculation⁴³. It is possible that a long-lasting DNA aptamer neutralizes ANSR
279 autoantibodies over an extended period, rather than only targeting the antibodies
280 present during the therapy, as is the case with IA-therapy. Moreover, IA-therapy can
281 only filter AABs out of the blood, whereas DNA aptamers can also act at the tissue
282 level.⁴⁴

283 Interestingly, changes in pro-inflammatory cytokine levels were detected after the IA-
284 therapy. While some cytokines, such as IL-2, IL-4, and IL-17A, were reduced
285 immediately after the final IA-therapy TGF β 1 levels were elevated. Other cytokines,
286 like IP-10 and MCP-1, were not significantly affected by the therapy. The reason for
287 the changes in cytokine levels after IA remains speculative. The different impact of IA
288 on certain cytokines demonstrates that this is not a pure mechanical cytokine
289 elimination. There might be a general reduction in inflammation after IA, as
290 autoantibodies drive inflammation via the activation of the complement system or
291 direct antibody-dependent activation of immune cells.⁴⁵⁻⁴⁷ Furthermore, patients with
292 infectious or autoimmune diseases have autoantibodies against some cytokines that
293 bind to the IA column, which could also remove bound cytokines.⁴⁸⁻⁵⁰

294 While the presence of ANSR autoantibodies indicate a defective immunotolerance
295 after a viral infection,^{51,52} the existence of soluble spike protein in post-COVID
296 patients may indicate an active, persistent infection with SARS-CoV-2 viruses as it is
297 currently discussed. Persistent viral reservoirs are known from other RNA viruses
298 such as Ebola or Measles and are found in various tissues.^{53,54} The presence of

299 soluble SARS-CoV-2 spike protein in 6 of the 12 patients suggests that half of the
300 post-COVID patients in this study contain active virus reservoirs in their tissues that
301 release spike protein into the bloodstream. Interestingly, spike protein was also
302 largely removed from the patients' blood with IA-therapy, even though they were not
303 expected to bind to the Ig-column. However, since high titers of SARS-CoV-2 spike
304 protein specific antibodies were detected in all patients, it is likely that these
305 antibodies bound to soluble spike protein, leading to their removal along with the
306 antibodies during IA-therapy. Notable, there was no improvement in self-reported
307 symptoms after IA-therapy associated with the removal of spike proteins in patients
308 with soluble spike protein, which is consistent with the observation that spike positive
309 patients do not show significant correlations between spike level and ME/CSF test
310 scores. Whether and how soluble spike protein itself has a direct pathogenic effect or
311 if the active virus reservoirs lead to the manifestation and exacerbation of post-
312 COVID symptoms is not yet clear. It is discussed that soluble spike protein directly
313 leads to the formation of fibrin and amolytic microclots, which should be prevented by
314 removing spike protein from the body.⁵⁵ Additionally, it has been shown in mice that
315 spike protein injected in the brain can lead to neuropsychological impairments that
316 are similar to post-COVID symptoms,⁵⁶ although it remains highly unclear, whether
317 the spike protein crosses the blood-brain barrier in humans and can be responsible
318 for similar mechanisms. However, since IA-therapy does not address the source of
319 the soluble spike protein, the ongoing production of spike protein due to persistent
320 infection may prevent a beneficial effect. This would be supported by the fact that the
321 level of spike protein almost returned to its original level shortly after the last IA
322 session. It is also noteworthy that a strong correlation between the amount of all
323 ANSR autoantibodies tested and most pro-inflammatory cytokines was only seen in
324 the spike positive patients, which is only the case for β 1 AAB in the spike negative
325 patients. It could be assumed that a persistent infection leads to increased
326 inflammation and generation of auto-reactive antibodies. Moreover, previous studies
327 demonstrated a clear association between inflammation and autoimmunity.⁵⁷

328 Also some changes at the cellular level were observed after IA-therapy. There was a
329 significant reduction in CD4⁺ central memory and follicular helper T cells,
330 accompanied by an increase in the frequency of naive T cells. A direct interaction
331 and removal of the cells by the Ig-binding apheresis column can be excluded due to
332 the high specificity of the column.⁵⁸ However, the IA procedure might lead to a

333 temporary redistribution of T cell subsets within the body. The stress associated with
334 the treatment could trigger a short-term migration of T cells from the bloodstream to
335 various tissues, causing an apparent reduction of these cells in the peripheral blood.
336 Additionally, the observed changes in the cytokine profile, which is fundamental for T
337 cell homeostasis, could impact the maintenance of these T cell populations and result
338 in alterations in the distribution of sub-populations.⁵⁹ One difficulty with persistent and
339 chronic infections is that ongoing activation induced by constant antigen presence
340 can lead to exhaustion and changes in the differentiation of T cells.^{60,61}
341 Consequently, it was shown that T cells from post-COVID patients express higher
342 levels of exhaustion markers PD-1, CTLA-4 and Tim-3.^{62,63} Although this study did
343 not compare the levels of exhaustion markers or the T cell frequencies between post-
344 COVID patients and convalescent controls, any differences in the frequency of ANSR
345 lysate-specific or spike protein-specific T cells and their PD-1, CTLA-4 and Tim-3
346 expressing T cell subsets before and one month after IA-therapy have been
347 observed. These data suggest that even though these antigens were almost
348 completely removed immediately after therapy, IA-therapy has a short effect on these
349 molecules and obviously no modulating effect on T cells.

350 The fact that there was no improvement in the patients' perception of their symptoms
351 may also be related to the IA procedure itself. IA-therapy is an invasive procedure
352 that poses a challenge for all patients due to the long duration and use of a Shaldon
353 catheters. Especially for patients in a poor general condition, such as post-COVID
354 patients, this can further increase the level of suffering. In these cases, subjectively
355 reported symptoms may not align with objective measurements

356 This study has some limitations. This is an observational study, and a randomized
357 control trial including a placebo group is needed to verify the beneficial effect of IA-
358 therapy. Furthermore, the small sample size of 12 patients reduces the statistical
359 power, potentially masking significant changes. Fortunately, much of the laboratory
360 data is consistent enough among patients to allow reasonably firm conclusions.
361 However, the study does not prove a causal relation between ANSR autoantibodies
362 and ME/CFS symptoms, since IA removes other immunoglobulins as well. Another
363 limitation is a potential practicing effect in the neuropsychological tests. However, it
364 has been shown that these can be eliminated or limited by the selection of tests⁶⁴.
365 The follow up at day 30 after IA is relatively short, and it will be necessary to see if

366 the observed improvements are persistent and even lead to a self-assessed
367 improvement.

368 In summary, this study demonstrates that IA-therapy in patients with post-COVID
369 disease and ME/CSF symptoms leads to a significant reduction in autoantibodies,
370 soluble spike protein, and inflammatory cytokines. This is accompanied by moderate
371 improvements in neuropsychological parameters, though it does not influence the
372 patients' subjective perception of their symptoms. These data lay the foundation for
373 further research to determine the extent of these observed benefits for patients and
374 whether this treatment should be considered standard for post-COVID care in the
375 future.

376 **Methods**

377 **Study population and design**

378 This observational study involved 12 post-COVID patients exhibiting a predominance
379 of ME/CFS symptoms alongside the presence of ANSR autoantibodies ($\beta 1 > 15$
380 U/mL; $\beta 2 > 8$ U/mL; M3 > 6 U/mL; M4 > 10.7 U/mL) and neurological impairments.
381 Age over 18 years, ME/CSF syndrome, the presence of 3 of the 4 ANSR AABs and
382 written consent were defined as inclusion criteria. Patients underwent
383 immunoadsorption therapy and blood samples were collected from patients before
384 the initial session, immediately post-treatment, and again after an additional 30 days
385 (Figure 1). The study was approved by the ethical committee of Ruhr university
386 Bochum (Reg.-Nr. 23-7752) and all participants provided a written informed
387 consents.

388 **Immunoadsorption Therapy**

389 Patients underwent a course of TheraSorb - Ig omni 5 adsorber (Miltenyi, Germany)
390 immunoadsorption therapy comprising 5 sessions over a span of 10 days aimed at
391 eliminating IgG antibodies. The therapy was carried out at Marien Hospital Herne in
392 Medical Clinic 1 for Internal Medicine under the supervision of a professional dialysis
393 unit.

394 **Preparation of PBMCs**

395 Peripheral blood was collected in S-Monovette K3 EDTA blood collection tubes
396 (Sarstedt, Germany). Collected blood was pre-diluted in PBS/BSA (Gibco, USA) at a
397 1:1 ratio and underlaid with 15 mL Ficoll-Paque Plus (GE Healthcare, USA). Tubes
398 were centrifuged at 800 g for 20 minutes at room temperature. Isolated PBMC were
399 washed twice with PBS/BSA and stored at -80°C until use as previously described⁶⁵.

400 **Antigen stimulation of T cells**

401 Isolated PBMC were stimulated with $1\mu\text{g/ml}$ Sars-CoV-2 OPPs (Miltenyi, Germany),
402 $1\mu\text{g/ml}$ $\beta 1+\beta 2$ or $1\mu\text{g/ml}$ M3+M4 purified cell lysates (Biotrend, Germany). 2.5×10^6
403 PBMCs were plated for each condition in 96-UWell Plates in RPMI media (Life
404 Technologies), supplemented with 1% Penicillin-Streptomycin-Glutamine (Sigma
405 Aldrich, USA), and 10% FCS (PAN-Biotech, USA) and were stimulated or left
406 untreated as a control for 16 hours. As a positive control, cells were stimulated with
407 SEB ($1\mu\text{g/ml}$, Sigma Aldrich, USA) or left untreated as a negative control. After 2

408 hours, Brefeldin A (1µg/ml, Sigma Aldrich, USA) was added. As previously applied by
409 our groups and others, antigen-specific responses were considered positive after the
410 non-specific background was subtracted, and more than 0.001% or at least 15
411 positive cells were detectable. Negative values were set to zero.

412 **Measurement of autoantibodies to GPCR**

413 Serum was collected in a S-Monovette Serum collection tube (Sarstedt, Germany)
414 and processed per manufacturer's instructions. Purified serum was stored at -20 °C
415 until use. ELISA systems for detection of autoantibodies against β -1 Adrenergic
416 Receptor (β 1), β -2 Adrenergic Receptor (β 2), Muscarinergic Choline Receptor 3
417 (M3), and Muscarinergic Choline Receptor 4 (M4) were all obtained from CellTrend,
418 Germany. Autoantibodies in serum were determined per manufacturer's instructions
419 and normalized using the provided standard. The following cut-offs were used to
420 define presence of autoantibodies: β 1: >15 U/ml; β 2: >8 U/ml; M3: >6 U/ml; M4:
421 >10.7 U/ml.

422 **QPCR measurement of EBV virus titer**

423 Peripheral blood samples were monitored for EBV by qPCR. DNA was isolated from
424 whole blood samples using AltoStar Purification Kit 1.5 (Altostar, Germany) and
425 qPCR was performed using AltoStar EBV PCR Kit 1.5 following the manufacturer's
426 instructions. Both Kits were performed on an AltoStar AM16 pipetting robot and
427 qPCR was measured on an BioRad C1000 Thermal Cycler. The detection level was
428 determined as the lowest viral load measured within the range of linearity (250
429 copies/ml).

430 **Cytokine analysis**

431 Purified serum was stored at -20 °C until use. The level of the cytokines IL-4, IL-2,
432 IP-10 (CXCL10), IL-1 β , TNF- α , MCP-1 (CCL2), IL-17A, IL-6, IL-10, IFN- γ , IL-12p70,
433 IL-8 (CXCL8), and TGF- β 1 (free active) was assessed using the LEGENDplex
434 Human Essential Immune Response Panel (BioLegend, San Diego, USA) per
435 manufacturers instruction and acquired on a CytoFLEX (Beckman Coulter, Germany)
436 flow cytometer. Briefly, serum was incubated with beads coated with antibodies for
437 one of the analyzed cytokines together with a secondary antibody and phycoerythrin-
438 conjugated (PE) detection antibody. Each cytokine is detectable by the bead size and
439 level of allophycocyanin (APC) within the bead, and the intensity of PE is relative to

440 the levels of the cytokine in the sample. The measured fluorescence intensities were
441 normalized using the provided cytokine standard.

442 **ME/CFS symptoms and neuropsychological evaluation**

443 Long-COVID symptoms were quantified using a 19 items questionnaire based on the
444 ISARIC COVID-19 follow-up study protocol. To quantify the severity of mental and
445 physical fatigue, all patients completed the Chalder fatigue scale, Munich Berlin
446 Symptom Questionnaire (MBSQ) and Epworth Sleepiness Scale (ESS). Physical
447 function and impairment were assessed by the Bell disability scale and the Short
448 Form Health Survey-36 (SF-36). Additionally, hand grip strength was measured as an
449 objective parameter for physical impairment using a hydraulic hand dynamometer
450 (Saehan, Germany). Furthermore, dysautonomic symptoms were evaluated using the
451 COMPASS-31 score. All neuropsychological assessments were conducted using the
452 German version of the “Consortium to Establish a Registry for Alzheimer’s Disease
453 Neuropsychological Assessment Battery” (CERAD). The standard assessment,
454 which includes evaluation of verbal fluency (animal naming), a modified version of the
455 Boston Naming Test, global cognition (Mini-Mental State examination), verbal
456 memory (word list learning, delayed recall), as well as constructional practice and
457 delayed recall, was widened out by additional items on processing speed (Trail Making
458 Test A) and executive functioning (Trail Making Test B, letter fluency: S-words).

459 **Spike Protein Elisa**

460 Serum was collected in a S-Monovette Serum collection tube (Sarstedt, Germany)
461 and stored at -20 °C until use. The concentration of spike protein was assessed
462 using the Human SARS-CoV.2 RBD Elisa Kit (Invitrogen, Thermo Fisher, USA). The
463 Elisa was performed according to the manufacturers technical manual and no
464 alterations were implemented. The optical density of the plates was determined using
465 a Asys UVM 340.

466 **Antibodies**

467 Antigen specific T cells (all antibodies are from BioLegend (USA) unless otherwise
468 noted): Surface staining: CCR7 (CD197)-PerCP-Cy5.5; clone: G043H7, CD4-A700;
469 clone: OKT4, LD eFluor780 (eBioscience, USA), CD8-V500; clone: RPA-T8 (BD
470 Biosciences), CD45RA-BV605; clone: HI100. Intracellular staining: CD137 (4-1BB)-
471 PE-Cy7; clone: 4B4-1, CD154 (CD40L)-A647; clone: 24-31, TNFa-eFluor450; clone:
472 MAAb11 (eBioscience, USA), CD3-BV785; clone: OKT3, PD-1-PE; clone: A17188A,

473 Tim-3-VioBright-Fitc; clone: REA635 (Miltenyi, Germany), CTLA-4-BV421; clone:
474 BNI3, Lag-3-BV650; clone: 11C3C65. Fixable Viability Dye eFluor 780 (eBioscience,
475 USA) was used for live/dead discrimination.

476 **Flow Cytometry**

477 Stimulated PBMC were extracellular stained with optimal concentrations of antibodies
478 for 10 minutes at room temperature in the dark. Cells were washed twice with
479 PBS/BSA before preparation for intracellular staining using the Intracellular Fixation &
480 Permeabilization Buffer Set (Thermo Fisher Scientific) as per manufacturer's
481 instructions. Fixed and permeabilized cells were stained for 30 minutes at room
482 temperature in the dark with an optimal dilution of antibodies against the intracellular
483 antigen.

484 All samples were immediately acquired on a CytoFlex flow cytometer (Beckman
485 Coulter). Quality control was performed daily using the recommended CytoFlex Daily
486 QC Fluorospheres (Beckman Coulter). No modification to the compensation matrices
487 was required throughout the study. Flow cytometry data were analyzed using FlowJo
488 version 10.6.2 (BD Biosciences); gating strategies are presented in Supplemental
489 Figures S5+S6.

490 **Statistical analysis**

491 Statistical analysis was performed using R, version 4.2.1. Categorical variables are
492 summarized as numbers and frequencies; quantitative variables are reported as
493 mean \pm SD. No data transformation was used. Violin plots depict the median and the
494 first and third quartiles. The whiskers correspond to 1.5 times the interquartile range.
495 All applied statistical tests are paired and two-sided. Dotted lines between violins
496 indicate the individual patients. Differences in quantitative variables between all three
497 groups are analyzed using non-parametric Wilcoxon test. P values below 0.050 were
498 considered significant. P values were not corrected for multiple testing, as this study
499 was of exploratory nature^{66,67}. The normalization standard for the ELISA results was
500 calculated using a four parameter logistic regression. Parameter correlation was
501 assessed using Spearman's rank correlation coefficient.

502 Author contributions

503 Conceptualization: T.W. and N.B.; Data curation: M.A., L.W., K.R. and U.S.; Formal
504 analysis: M.A., L.W., K.R. and U.S.; Funding acquisition: N.B.; Investigation: M.A.,
505 L.W., K.R., S.S., J.K., S.K., U.S. and N.B.; Methodology: M.A., U.S. and N.B.;
506 Resources: A.D., F.S. and T.W.; Visualization: M.A. and K.R.; Writing – original draft:
507 M.A., L.W., K.R., U.S. and N.B.; Writing - review & editing: M.A., L.W., K.R., U.S. and
508 N.B.;

509 **Acknowledgments**

510 We want to express our deepest gratitude to the patients who donated their blood
511 samples and clinical data for this project. We thank Miltenyi Biotec who supported our
512 study by providing materials and equipment (TheraSorb columns) for
513 Immunoabsorption. This work was further supported by DFG grants NFDI4
514 (501875662)

515 **Conflict of interest**

516 The study was initiated by the investigators themselves. They independently created
517 the study without any external guidance or involvement from entities like Miltenyi
518 Biotec or any other undisclosed parties, pertaining to its design, analysis, data
519 interpretation or manuscript approval. The authors themselves did not receive any
520 payment related to this study and have stated that they have no conflicting interests.

521 References

- 522 1. Davis, H.E., McCorkell, L., Vogel, J.M., and Topol, E.J. (2023). Long COVID:
523 major findings, mechanisms and recommendations. *Nat. Rev. Microbiol.* 21, 133–
524 146. <https://doi.org/10.1038/s41579-022-00846-2>.
- 525 2. Carfi, A., Bernabei, R., Landi, F., and for the Gemelli Against COVID-19 Post-
526 Acute Care Study Group (2020). Persistent Symptoms in Patients After Acute
527 COVID-19. *JAMA* 324, 603. <https://doi.org/10.1001/jama.2020.12603>.
- 528 3. Ramadan, M.S., Bertolino, L., Zampino, R., Durante-Mangoni, E., Durante-
529 Mangoni, E., Iossa, D., Bertolino, L., Ursi, M.P., D'Amico, F., Karruli, A., et al.
530 (2021). Cardiac sequelae after coronavirus disease 2019 recovery: a systematic
531 review. *Clin. Microbiol. Infect.* 27, 1250–1261.
532 <https://doi.org/10.1016/j.cmi.2021.06.015>.
- 533 4. Carvalho-Schneider, C., Laurent, E., Lemaigen, A., Beaufiles, E., Bourbao-
534 Tournois, C., Laribi, S., Flament, T., Ferreira-Maldent, N., Bruyère, F., Stefic, K.,
535 et al. (2021). Follow-up of adults with noncritical COVID-19 two months after
536 symptom onset. *Clin. Microbiol. Infect.* 27, 258–263.
537 <https://doi.org/10.1016/j.cmi.2020.09.052>.
- 538 5. Daines, L., Zheng, B., Elneima, O., Harrison, E., Lone, N.I., Hurst, J.R., Brown,
539 J.S., Sapey, E., Chalmers, J.D., Quint, J.K., et al. (2023). Characteristics and risk
540 factors for post-COVID-19 breathlessness after hospitalisation for COVID-19.
541 *ERJ Open Res.* 9, 00274–02022. <https://doi.org/10.1183/23120541.00274-2022>.
- 542 6. Jaywant, A., Gunning, F.M., Oberlin, L.E., Santillana, M., Ognyanova, K.,
543 Druckman, J.N., Baum, M.A., Lazer, D., and Perlis, R.H. (2024). Cognitive
544 Symptoms of Post-COVID-19 Condition and Daily Functioning. *JAMA Netw.*
545 *Open* 7, e2356098. <https://doi.org/10.1001/jamanetworkopen.2023.56098>.
- 546 7. Li, Z., Zhang, Z., Zhang, Z., Wang, Z., and Li, H. (2023). Cognitive impairment
547 after long COVID-19: current evidence and perspectives. *Front. Neurol.* 14.
548 <https://doi.org/10.3389/fneur.2023.1239182>.
- 549 8. Quan, M., Wang, X., Gong, M., Wang, Q., Li, Y., and Jia, J. (2023). Post-COVID
550 cognitive dysfunction: current status and research recommendations for high risk
551 population. *Lancet Reg. Health – West. Pac.* 38.
552 <https://doi.org/10.1016/j.lanwpc.2023.100836>.
- 553 9. Sotzny, F., Filgueiras, I.S., Kedor, C., Freitag, H., Wittke, K., Bauer, S.,
554 Sepúlveda, N., Mathias da Fonseca, D.L., Baiocchi, G.C., Marques, A.H.C., et al.
555 (2022). Dysregulated autoantibodies targeting vaso- and immunoregulatory
556 receptors in Post COVID Syndrome correlate with symptom severity. *Front.*
557 *Immunol.* 13, 981532. <https://doi.org/10.3389/fimmu.2022.981532>.
- 558 10. Iwasaki, A., and Putrino, D. (2023). Why we need a deeper understanding of the
559 pathophysiology of long COVID. *Lancet Infect. Dis.* 23, 393–395.
560 [https://doi.org/10.1016/S1473-3099\(23\)00053-1](https://doi.org/10.1016/S1473-3099(23)00053-1).
- 561 11. Machkovech, H.M., Hahn, A.M., Wang, J.G., Grubaugh, N.D., Halfmann, P.J.,
562 Johnson, M.C., Lemieux, J.E., O'Connor, D.H., Piantadosi, A., Wei, W., et al.
563 (2024). Persistent SARS-CoV-2 infection: significance and implications. *Lancet*
564 *Infect. Dis.* 24, e453–e462. [https://doi.org/10.1016/S1473-3099\(23\)00815-0](https://doi.org/10.1016/S1473-3099(23)00815-0).
- 565 12. Ghafari, M., Hall, M., Golubchik, T., Ayoubkhani, D., House, T., MacIntyre-
566 Cockett, G., Fryer, H.R., Thomson, L., Nurtay, A., Kemp, S.A., et al. (2024).
567 Prevalence of persistent SARS-CoV-2 in a large community surveillance study.
568 *Nature* 626, 1094–1101. <https://doi.org/10.1038/s41586-024-07029-4>.
- 569 13. Tejerina, F., Catalan, P., Rodriguez-Grande, C., Adan, J., Rodriguez-Gonzalez,
570 C., Muñoz, P., Aldamiz, T., Diez, C., Perez, L., Fanciulli, C., et al. (2022). Post-
571 COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in

- 572 patients with persistent symptoms after COVID-19. *BMC Infect. Dis.* 22, 211.
573 <https://doi.org/10.1186/s12879-022-07153-4>.
- 574 14. Ceulemans, L.J., Khan, M., Yoo, S.-J., Zapiec, B., Van Gerven, L., Van
575 Slambrouck, J., Vanstapel, A., Van Raemdonck, D., Vos, R., Wauters, E., et al.
576 (2021). Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19.
577 *Lancet Respir. Med.* 9, e78–e79. [https://doi.org/10.1016/S2213-2600\(21\)00240-](https://doi.org/10.1016/S2213-2600(21)00240-)
578 X.
- 579 15. Craddock, V., Mahajan, A., Spikes, L., Krishnamachary, B., Ram, A.K., Kumar,
580 A., Chen, L., Chalise, P., and Dhillon, N.K. (2023). Persistent Circulation of
581 Soluble and Extracellular vesicle-linked Spike Protein in Individuals with Post-
582 Acute Sequelae of COVID-19. *J. Med. Virol.* 95, e28568.
583 <https://doi.org/10.1002/jmv.28568>.
- 584 16. Craddock, V., Mahajan, A., Krishnamachary, B., Spikes, L., Chalise, P., and
585 Dhillon, N.K. (2022). Persistent Presence of Spike protein and Viral RNA in the
586 Circulation of Individuals with Post-Acute Sequelae of COVID-19. Preprint at
587 medRxiv, <https://doi.org/10.1101/2022.08.07.22278520>
588 <https://doi.org/10.1101/2022.08.07.22278520>.
- 589 17. Swank, Z., Senussi, Y., Manickas-Hill, Z., Yu, X.G., Li, J.Z., Alter, G., and Walt,
590 D.R. (2023). Persistent Circulating Severe Acute Respiratory Syndrome
591 Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019
592 Sequelae. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 76, e487–e490.
593 <https://doi.org/10.1093/cid/ciac722>.
- 594 18. Su, Y., Yuan, D., Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S.,
595 Zhang, R., Xie, J., et al. (2022). Multiple early factors anticipate post-acute
596 COVID-19 sequelae. *Cell* 185, 881-895.e20.
597 <https://doi.org/10.1016/j.cell.2022.01.014>.
- 598 19. Dobrowolska, K., Zarębska-Michaluk, D., Poniedziałek, B., Jaroszewicz, J.,
599 Flisiak, R., and Rzymiski, P. (2023). Overview of autoantibodies in COVID-19
600 convalescents. *J. Med. Virol.* 95, e28864. <https://doi.org/10.1002/jmv.28864>.
- 601 20. Seibert, F.S., Stervbo, U., Wiemers, L., Skrzypczyk, S., Hogeweg, M., Bertram,
602 S., Kurek, J., Anft, M., Westhoff, T.H., and Babel, N. (2023). Severity of
603 neurological Long-COVID symptoms correlates with increased level of
604 autoantibodies targeting vasoregulatory and autonomic nervous system
605 receptors. *Autoimmun. Rev.* 22, 103445.
606 <https://doi.org/10.1016/j.autrev.2023.103445>.
- 607 21. Zubchenko, S., Kril, I., Nadizhko, O., Matsyura, O., and Chopyak, V. (2022).
608 Herpesvirus infections and post-COVID-19 manifestations: a pilot observational
609 study. *Rheumatol. Int.* 42, 1523–1530. <https://doi.org/10.1007/s00296-022-05146->
610 9.
- 611 22. Elizalde-Díaz, J.P., Miranda-Narváez, C.L., Martínez-Lazcano, J.C., and
612 Martínez-Martínez, E. (2022). The relationship between chronic immune
613 response and neurodegenerative damage in long COVID-19. *Front. Immunol.* 13,
614 1039427. <https://doi.org/10.3389/fimmu.2022.1039427>.
- 615 23. Nlandu, Y., Tannor, E.K., Bafemika, T., and Makulo, J.-R. (2024). Kidney damage
616 associated with COVID-19: from the acute to the chronic phase. *Ren. Fail.* 46,
617 2316885. <https://doi.org/10.1080/0886022X.2024.2316885>.
- 618 24. Rizvi, A.A., Kathuria, A., Mahmeed, W.A., Al-Rasadi, K., Al-Alawi, K., Banach, M.,
619 Banerjee, Y., Ceriello, A., Cesur, M., Cosentino, F., et al. (2022). Post-COVID
620 syndrome, inflammation, and diabetes. *J. Diabetes Complications* 36, 108336.
621 <https://doi.org/10.1016/j.jdiacomp.2022.108336>.

- 622 25. Pretorius, E., Venter, C., Laubscher, G.J., Kotze, M.J., Oladejo, S.O., Watson,
623 L.R., Rajaratnam, K., Watson, B.W., and Kell, D.B. (2022). Prevalence of
624 symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in
625 individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
626 *Cardiovasc. Diabetol.* 21, 148. <https://doi.org/10.1186/s12933-022-01579-5>.
- 627 26. Charfeddine, S., Ibn Hadj Amor, H., Jdidi, J., Torjmen, S., Kraiem, S., Hammami,
628 R., Bahloul, A., Kallel, N., Moussa, N., Touil, I., et al. (2021). Long COVID 19
629 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights
630 From TUN-EndCOV Study. *Front. Cardiovasc. Med.* 8, 745758.
631 <https://doi.org/10.3389/fcvm.2021.745758>.
- 632 27. Tölle, M., Freitag, H., Antelmann, M., Hartwig, J., Schuchardt, M., van der Giet,
633 M., Eckardt, K.-U., Grabowski, P., and Scheibenbogen, C. (2020). Myalgic
634 Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat
635 Immunoabsorption. *J. Clin. Med.* 9, 2443. <https://doi.org/10.3390/jcm9082443>.
- 636 28. Scheibenbogen, C., Loebel, M., Freitag, H., Krueger, A., Bauer, S., Antelmann,
637 M., Doehner, W., Scherbakov, N., Heidecke, H., Reinke, P., et al. (2018).
638 Immunoabsorption to remove β_2 adrenergic receptor antibodies in Chronic
639 Fatigue Syndrome CFS/ME. *PLoS ONE* 13, e0193672.
640 <https://doi.org/10.1371/journal.pone.0193672>.
- 641 29. Stein, E., Heindrich, C., Wittke, K., Kedor, C., Kim, L., Freitag, H., Krüger, A.,
642 Tölle, M., and Scheibenbogen, C. (2023). Observational Study of Repeat
643 Immunoabsorption (RIA) in Post-COVID ME/CFS Patients with Elevated β_2 -
644 Adrenergic Receptor Autoantibodies—An Interim Report. *J. Clin. Med.* 12, 6428.
645 <https://doi.org/10.3390/jcm12196428>.
- 646 30. Gao, Z., Feng, Y., Xu, J., and Liang, J. (2022). T-cell exhaustion in immune-
647 mediated inflammatory diseases: New implications for immunotherapy. *Front.*
648 *Immunol.* 13, 977394. <https://doi.org/10.3389/fimmu.2022.977394>.
- 649 31. Luo, Q., Ye, J., Zeng, L., Luo, Z., Deng, Z., Li, X., Guo, Y., Huang, Z., and Li, J.
650 (2017). Elevated expression of PD-1 on T cells correlates with disease activity in
651 rheumatoid arthritis. *Mol. Med. Rep.* <https://doi.org/10.3892/mmr.2017.8204>.
- 652 32. Cabral-Marques, O., and Riemekasten, G. (2017). Functional autoantibodies
653 targeting G protein-coupled receptors in rheumatic diseases. *Nat. Rev.*
654 *Rheumatol.* 13, 648–656. <https://doi.org/10.1038/nrrheum.2017.134>.
- 655 33. Karschnia, M., Zweck, E., Scheiber, D., Heidecke, H., Barthuber, C., Kelm, M.,
656 Roden, M., Westenfeld, R., Szendroedi, J., and Boege, F. (2022). Associations of
657 GPCR autoantibodies with clinical, histological, metabolic and hemodynamic
658 features in non-ischemic heart failure patients. *Eur. Heart J.* 43, ehac544.757.
659 <https://doi.org/10.1093/eurheartj/ehac544.757>.
- 660 34. Wallukat, G., and Schimke, I. (2014). Agonistic autoantibodies directed against G-
661 protein-coupled receptors and their relationship to cardiovascular diseases.
662 *Semin. Immunopathol.* 36, 351–363. <https://doi.org/10.1007/s00281-014-0425-9>.
- 663 35. Wallukat, G., Hohberger, B., Wenzel, K., Fürst, J., Schulze-Rothe, S., Wallukat,
664 A., Hönicke, A.-S., and Müller, J. (2021). Functional autoantibodies against G-
665 protein coupled receptors in patients with persistent Long-COVID-19 symptoms.
666 *J. Transl. Autoimmun.* 4, 100100. <https://doi.org/10.1016/j.jtauto.2021.100100>.
- 667 36. Cabral-Marques, O., Halpert, G., Schimke, L.F., Ostrinski, Y., Vojdani, A.,
668 Baiocchi, G.C., Freire, P.P., Filgueiras, I.S., Zyskind, I., Lattin, M.T., et al. (2022).
669 Autoantibodies targeting GPCRs and RAS-related molecules associate with
670 COVID-19 severity. *Nat. Commun.* 13, 1220. <https://doi.org/10.1038/s41467-022-28905-5>.
- 671

- 672 37. Cabral-Marques, O., Halpert, G., Schimke, L.F., Ostrinski, Y., Zyskind, I., Lattin,
673 M.T., Tran, F., Schreiber, S., Marques, A.H.C., Filgueiras, I.S., et al. (2021). The
674 relationship between autoantibodies targeting GPCRs and the renin-angiotensin
675 system associates with COVID-19 severity. Preprint at medRxiv,
676 <https://doi.org/10.1101/2021.08.24.21262385>
677 <https://doi.org/10.1101/2021.08.24.21262385>.
- 678 38. Hall, J., Bourne, K.M., Vernino, S., Hamrefors, V., Kharraziha, I., Nilsson, J.,
679 Sheldon, R.S., Fedorowski, A., and Raj, S.R. (2022). Detection of G Protein-
680 Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome
681 Using Standard Methodology. *Circulation* 146, 613–622.
682 <https://doi.org/10.1161/CIRCULATIONAHA.122.059971>.
- 683 39. Kwan, A.C., Ebinger, J.E., Wei, J., Le, C.N., Oft, J.R., Zabner, R., Teodorescu,
684 D., Botting, P.G., Navarrette, J., Ouyang, D., et al. (2022). Apparent risks of
685 postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination
686 and SARS-Cov-2 Infection. *Nat. Cardiovasc. Res.* 1, 1187–1194.
687 <https://doi.org/10.1038/s44161-022-00177-8>.
- 688 40. Mallick, D., Goyal, L., Chourasia, P., Zapata, M.R., Yashi, K., and Surani, S.
689 (2023). COVID-19 Induced Postural Orthostatic Tachycardia Syndrome (POTS):
690 A Review. *Cureus* 15, e36955. <https://doi.org/10.7759/cureus.36955>.
- 691 41. Kedor, C., Freitag, H., Meyer-Armdt, L., Wittke, K., Hanitsch, L.G., Zoller, T.,
692 Steinbeis, F., Haffke, M., Rudolf, G., Heidecker, B., et al. (2022). A prospective
693 observational study of post-COVID-19 chronic fatigue syndrome following the first
694 pandemic wave in Germany and biomarkers associated with symptom severity.
695 *Nat. Commun.* 13, 5104. <https://doi.org/10.1038/s41467-022-32507-6>.
- 696 42. Ruhe, J., Giszas, B., Schlosser, M., Reuken, P.A., Wolf, G., and Stallmach, A.
697 (2023). Immune adsorption for the treatment of fatigue-dominant long-/post-
698 COVID syndrome. *Dtsch. Ärztebl. Int.* <https://doi.org/10.3238/arztebl.m2023.0073>.
- 699 43. Hohberger, B., Harrer, T., Mardin, C., Kruse, F., Hoffmanns, J., Rogge, L.,
700 Heltmann, F., Moritz, M., Szewczykowski, C., Schottenhamml, J., et al. (2021).
701 Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled
702 Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-
703 19 Infection. *Front. Med.* 8, 754667. <https://doi.org/10.3389/fmed.2021.754667>.
- 704 44. Wu, X., Chen, J., Wu, M., and Zhao, J.X. (2015). Aptamers: Active Targeting
705 Ligands for Cancer Diagnosis and Therapy. *Theranostics* 5, 322–344.
706 <https://doi.org/10.7150/thno.10257>.
- 707 45. Daha, N.A., Banda, N.K., Roos, A., Beurskens, F.J., Bakker, J.M., Daha, M.R.,
708 and Trouw, L.A. (2011). Complement activation by (auto-) antibodies. *Mol.*
709 *Immunol.* 48, 1656–1665. <https://doi.org/10.1016/j.molimm.2011.04.024>.
- 710 46. Mathsson, L., Ahlin, E., Sjöwall, C., Skogh, T., and Rönnelid, J. (2007). Cytokine
711 induction by circulating immune complexes and signs of in-vivo complement
712 activation in systemic lupus erythematosus are associated with the occurrence of
713 anti-Sjögren's syndrome A antibodies. *Clin. Exp. Immunol.* 147, 513–520.
714 <https://doi.org/10.1111/j.1365-2249.2006.03313.x>.
- 715 47. Nielsen, C.H., and Bendtzen, K. (2012). Immunoregulation by naturally occurring
716 and disease-associated autoantibodies: binding to cytokines and their role in
717 regulation of T-cell responses. *Adv. Exp. Med. Biol.* 750, 116–132.
718 https://doi.org/10.1007/978-1-4614-3461-0_9.
- 719 48. Ku, C.-L., Chi, C.-Y., Bernuth, H. von, and Doffinger, R. (2020). Autoantibodies
720 against cytokines: phenocopies of primary immunodeficiencies? *Hum. Genet.*
721 139, 783. <https://doi.org/10.1007/s00439-020-02180-0>.

- 722 49. Cheng, A., and Holland, S.M. (2024). Anti-cytokine autoantibodies: mechanistic
723 insights and disease associations. *Nat. Rev. Immunol.* 24, 161–177.
724 <https://doi.org/10.1038/s41577-023-00933-2>.
- 725 50. Karin, N. (2018). Autoantibodies to Chemokines and Cytokines Participate in the
726 Regulation of Cancer and Autoimmunity. *Front. Immunol.* 9, 623.
727 <https://doi.org/10.3389/fimmu.2018.00623>.
- 728 51. Barzilai, O., Ram, M., and Shoenfeld, Y. (2007). Viral infection can induce the
729 production of autoantibodies. *Curr. Opin. Rheumatol.* 19, 636–643.
730 <https://doi.org/10.1097/BOR.0b013e3282f0ad25>.
- 731 52. Ludewig, B., Krebs, P., Metters, H., Tatzel, J., Türeci, Ö., and Sahin, U. (2004).
732 Molecular Characterization of Virus-induced Autoantibody Responses. *J. Exp.*
733 *Med.* 200, 637–646. <https://doi.org/10.1084/jem.20040358>.
- 734 53. Riddell, M.A., Moss, W.J., Hauer, D., Monze, M., and Griffin, D.E. (2007). Slow
735 clearance of measles virus RNA after acute infection. *J. Clin. Virol. Off. Publ. Pan*
736 *Am. Soc. Clin. Virol.* 39, 312–317. <https://doi.org/10.1016/j.jcv.2007.05.006>.
- 737 54. Varkey, J.B., Shantha, J.G., Crozier, I., Kraft, C.S., Lyon, G.M., Mehta, A.K.,
738 Kumar, G., Smith, J.R., Kainulainen, M.H., Whitmer, S., et al. (2015). Persistence
739 of Ebola Virus in Ocular Fluid during Convalescence. *N. Engl. J. Med.* 372, 2423–
740 2427. <https://doi.org/10.1056/NEJMoa1500306>.
- 741 55. Grobbelaar, L.M., Venter, C., Vlok, M., Ngoepe, M., Laubscher, G.J., Lourens,
742 P.J., Steenkamp, J., Kell, D.B., and Pretorius, E. (2021). SARS-CoV-2 spike
743 protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot
744 formation in COVID-19. *Biosci. Rep.* 41, BSR20210611.
745 <https://doi.org/10.1042/BSR20210611>.
- 746 56. Fontes-Dantas, F.L., Fernandes, G.G., Gutman, E.G., De Lima, E.V., Antonio,
747 L.S., Hammerle, M.B., Mota-Araujo, H.P., Colodeti, L.C., Araújo, S.M.B., Froz,
748 G.M., et al. (2023). SARS-CoV-2 Spike protein induces TLR4-mediated long-term
749 cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. *Cell Rep.*
750 42, 112189. <https://doi.org/10.1016/j.celrep.2023.112189>.
- 751 57. Xiang, Y., Zhang, M., Jiang, D., Su, Q., and Shi, J. (2023). The role of
752 inflammation in autoimmune disease: a therapeutic target. *Front. Immunol.* 14.
753 <https://doi.org/10.3389/fimmu.2023.1267091>.
- 754 58. C, S., F, K., L, P. da S., C, N., M, S., Le, B., K, K., J, B., C, S., A, L., et al. (2019).
755 Effectiveness of different immunoabsorption columns for anti-A/B antibody
756 depletion. *Atheroscler. Suppl.* 40.
757 <https://doi.org/10.1016/j.atherosclerosis.2019.08.030>.
- 758 59. Woodland, D.L., and Kohlmeier, J.E. (2009). Migration, maintenance and recall of
759 memory T cells in peripheral tissues. *Nat. Rev. Immunol.* 9, 153–161.
760 <https://doi.org/10.1038/nri2496>.
- 761 60. Kahan, S.M., Wherry, E.J., and Zajac, A.J. (2015). T Cell Exhaustion During
762 Persistent Viral Infections. *Virology* 0, 180–193.
763 <https://doi.org/10.1016/j.virol.2014.12.033>.
- 764 61. Saeidi, A., Zandi, K., Cheok, Y.Y., Saeidi, H., Wong, W.F., Lee, C.Y.Q., Cheong,
765 H.C., Yong, Y.K., Larsson, M., and Shankar, E.M. (2018). T-Cell Exhaustion in
766 Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal
767 Protective Immune Responses. *Front. Immunol.* 9, 2569.
768 <https://doi.org/10.3389/fimmu.2018.02569>.
- 769 62. Klein, J., Wood, J., Jaycox, J.R., Dhodapkar, R.M., Lu, P., Gehlhausen, J.R.,
770 Tabachnikova, A., Greene, K., Tabacof, L., Malik, A.A., et al. (2023).
771 Distinguishing features of long COVID identified through immune profiling. *Nature*
772 623, 139–148. <https://doi.org/10.1038/s41586-023-06651-y>.

- 773 63. Yin, K., Peluso, M.J., Luo, X., Thomas, R., Shin, M.-G., Neidleman, J., Andrew,
774 A., Young, K., Ma, T., Hoh, R., et al. (2023). Long COVID manifests with T cell
775 dysregulation, inflammation, and an uncoordinated adaptive immune response to
776 SARS-CoV-2. *BioRxiv Prepr. Serv. Biol.*, 2023.02.09.527892.
777 <https://doi.org/10.1101/2023.02.09.527892>.
- 778 64. Goldberg, T.E., Harvey, P.D., Wesnes, K.A., Snyder, P.J., and Schneider, L.S.
779 (2015). Practice effects due to serial cognitive assessment: Implications for
780 preclinical Alzheimer's disease randomized controlled trials. *Alzheimers Dement.*
781 *Diagn. Assess. Dis. Monit.* 1, 103–111.
782 <https://doi.org/10.1016/j.dadm.2014.11.003>.
- 783 65. Nienen, M., Stervbo, U., Mölder, F., Kaliszczyk, S., Kuchenbecker, L., Gayova, L.,
784 Schweiger, B., Jürchott, K., Hecht, J., Neumann, A.U., et al. (2019). The Role of
785 pre-existing cross-reactive central memory CD4 T-cells in vaccination with
786 previously unseen influenza strains. *Front. Immunol.* 10, 593.
787 <https://doi.org/10.3389/fimmu.2019.00593>.
- 788 66. Bender, R., and Lange, S. (2001). Adjusting for multiple testing—when and how?
789 *J. Clin. Epidemiol.* 54, 343–349. [https://doi.org/10.1016/S0895-4356\(00\)00314-0](https://doi.org/10.1016/S0895-4356(00)00314-0).
- 790 67. Li, G., Taljaard, M., Van Den Heuvel, E.R., Levine, M.Ah., Cook, D.J., Wells,
791 G.A., Devereaux, P.J., and Thabane, L. (2016). An introduction to multiplicity
792 issues in clinical trials: the what, why, when and how. *Int. J. Epidemiol.*, dyw320.
793 <https://doi.org/10.1093/ije/dyw320>.

794

795 **Figures and Tables:**

796 **Table 1. Cohort statistics**

Patients (n)	12
Age (Median [Q1-Q3])	50 [34.5-60]
Sex (Female; n (%))	8 (66.7%)
BMI (Median [Q1-Q3])	25.25 [22.1-26.9]
ME/CSF	12 (100%)
- Trigger SARS-CoV-2 infection	4 (33.3%)
- Other trigger, worsened by SARS-CoV-2 infection	8 (66.6%)

Comorbidities	
Arterial hypertension (n (%))	3 (25.0%)
Hyperlipidemia (n (%))	3 (25.0%)
COPD (n (%))	2 (16.7%)
Nicotine abuse (n (%))	2 (16.7%)
ESRD (n (%))	0 (0%)
Diabetes mellitus (n (%))	0 (0%)

797 BMI = Body mass index; COPD = chronic obstructive pulmonary disease; ESRD =
798 End stage renal disease

799

800 **Table 2 Reported symptoms, and self-rated physical and mental health**

Test	Parameter	Before IA	Follow-Up month)	(1 P-Value
Self rated physical and mental health				
SF-36 questionnaire				
	SF36-Total Score (Mean (SD))	29,7 (7.2)	31,7 (11.9)	0.57 [¥]
Physical health				
	Physical functioning (Mean (SD))	29,2 (16.2)	29,1 (18.8)	0.67 [¥]
	Role-physical (Mean (SD))	8,3 (15.6)	2,3 (7.2)	0.37 [¥]
Mental health				
	Mental health (Mean (SD))	51,7 (14.1)	60,7 (16.7)	0.12 [¥]
	Vitality (Mean (SD))	13,9 (13.19)	15,9 (12)	1.00 [¥]
	Role-emotional (Mean (SD))	66,6 (43.1)	81,8 (38.6)	0.41 [¥]
	Social functioning (Mean (SD))	13,4 (14)	17 (15.3)	0.31 [¥]
	General health (Mean (SD))	22 ± (2)	22,7 (12.3)	0.72 [¥]
	Bodily pain (Mean (SD))	28,6 (27)	36,2 (25.5)	0.09 [¥]
Other questionaries				
	Chalder Fatigue Scale (bm) (Mean (SD))	10.3 (0.9)	9.2 (2.2)	0.28 [¥]
	Bell Score (Mean (SD))	30 (7.4)	31.8 (11.1)	0.57 [¥]
	Canadian criteria for ME/CFS (n (%))	10/11 (90.9%)	9/11 (81.8%)	1.00*
	neurological/cognitive manifestations (n (%))	11/11 (100%)	10/11 (90.9%)	1.00*
	Immunological manifestations (n (%))	11/11 (100%)	11/11 (100%)	1.00*
Self reported symptoms				
	Flu-like symptoms (n (%))	10/11 (90.9%)	10/11 (90.9%)	1.00*
	Persistent cough (n (%))	1/11 (9.1%)	0/11 (0%)	1.00*
	Dyspnoe (n (%))	10/11 (90.9%)	8/11 (72.7%)	0.57*
	Tiredness (n (%))	11/11 (100%)	11/11 (100%)	1.00*
	Respiratory pain (n (%))	0/11 (0%)	1/11 (9.1%)	1.00*
	Thoracic Pain (n (%))	2/11 (18.2%)	1/11 (9.1%)	1.00*
	Odor changes (n (%))	2/11 (18.2%)	1/11 (9.1%)	1.00*
	Changes in taste (n (%))	2/11 (18.2%)	1/11 (9.1%)	1.00*
	Rhinorrhoe (n (%))	5/11 (45.5%)	6/11 (54.5%)	1.00*
	Cephalgien (n (%))	10/11 (90.9%)	11/11 (100%)	1.00*
	Myalgien (n (%))	8/11 (72.7%)	7/11 (63.6%)	1.00*
	Limb pain (n (%))	8/11 (72.7%)	8/11 (72.7%)	1.00*
	Unusual abdominal pain (n (%))	4/11 (36.4%)	4/11 (36.4%)	1.00*
	Nausea (n (%))	2/11 (18.2%)	0/11 (0%)	0.47*
	Diarrhoea (n (%))	3/11 (27.3%)	1/11 (9.1%)	0.59*
	Confusion, disorientation or drowsiness (n (%))	4/11 (36.4%)	2/11 (18.2%)	0.64*
	Brain Fog (n (%))	10/11 (90.9%)	11/11 (100%)	1.00*
	Sleep disorders (n (%))	9/11 (81.8%)	9/11 (81.8%)	1.00*
	Lack of drive (n (%))	3/11 (27.3%)	2/11 (18.2%)	1.00*

801 SD = standard deviation; bm = bimodular; * = Fisher's Exact Test, ¥ = Mann Whitney

802 U Test


803

804 **Figure 1. Influence of IA-Therapy on ANSR -AABs and physiological,**
805 **neuropsychological and cardiological health.** (A) Study protocol and time points for
806 various examinations and blood samples. (B) ELISA analysis of the concentration of $\beta 1/\beta 2$ -
807 adrenoceptors and muscarinic M3/M4 receptors before IA (D0), immediately after the last IA
808 session (D10), and 30 days later (D40). (C) Hand strength measurement before and 30 days
809 after the last IA session. (D) Results of the neuropsychological test battery CERAD-Plus
810 before and 30 days after the last IA session. Pairwise Man-Whitney U Test was performed.




811 **Figure 2. Temporary reduction of pro-inflammatory cytokines after IA-Therapy.**
812 Analysis of the cytokine profile of IA patients before IA, immediately after IA and 30 days
813 after the last IA. Pairwise Man-Whitney U Test was performed.

814 **Figure 3. Percentage of T cell populations and ANSR-specific T cells.** PBMCs from
815 patients were isolated before IA (D0), and 30 days after the last IA (D40) and stained with the
816 appropriate antibodies and analyzed in a flow-cytometer. (A+C) T cells were identified as
817 $CD3^+$ and $CD4^+$ or $CD8^+$. Naïve and memory T cells were distinguished by expression of
818 $CD45RA$ and $CCR7$, follicular helper cells by $CXCR5$ and exhausted T cells by expression of
819 $PD-1$. CM = Central Memory, EM = Effector Memory. (B+D) PBMC were stimulate for 18h
820 with SARS-CoV-2 Spike OPPs, $\beta 1/\beta 2$ -adrenoreceptors or muscarinic M3/M4 receptor cell
821 lysates, stained with the appropriate antibodies and analyzed in a flow-cytometer. Activated
822 T helper cells were identified as $CD4^+ CD154^+ CD137^+$ and activated cytotoxic T cells as
823 $CD8^+ CD137^+$. Pairwise Man-Whitney U Test was performed. Gating strategies are depicted
824 in supplementary figure S5+S6.


825 **Figure 4. Some of the patients have soluble spike protein, which is correlated with**
826 **ANSR AAB and blood levels of cytokines.** (A) Concentration of spike protein in all spike
827 positive patients (6/12). (B) Concentration of serum antibodies against SARS-CoV-2 spike
828 protein. (C) Percentage of spike protein specific T cells. PBMC were stimulated for 18h with
829 a SARS-CoV-2 spike protein overlapping peptide pool. Spike specific T helper cells were
830 identified as $CD4^+ CD154^+ CD137^+$ and spike specific cytotoxic T cells as $CD8^+ CD137^+$
831 among all CD4 or CD8 T cells. (D+E) Correlation matrices of spike+ and spike- patients with
832 ANSR AABs vs. blood cytokines (D) and neurological test (E). All collected values were
833 tested for correlation. *P*-values are shown as asterisks within the boxes. **p* < 0.05, ***p* < 0.01,
834 ****p* < 0.001, *****p* < 0.0001. Color grading refers to Spearman's rho rank correlation and is
835 indicated as legend underneath the correlation matrix.

A



- Before IA (Day 0)
- Blood analysis
 - Anamnesis
 - Cognitive Assessment Tests
 - Hand Strength test
- After IA (Day +10)
- Blood analysis
- Follow-up (Day +40)
- Blood analysis
 - Anamnesis
 - Cognitive Assessment Tests
 - Hand Strength test

B**C****D**


IL-4




IL-2

IL-1 β 


TNF




IL-17A




IL-12p70





IL-8




TGFB1







D



E

